Stockhub

BioMarin Pharmaceutical Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

3 August 2022

  • curprev 08:5908:59, 3 August 2022‎ Chris talk contribs‎ 2,018 bytes +2,018‎ Created page with "BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/BioMarin_Pharmaceutical_Inc.’